Seelos Therapeutics, Inc. Common Stock
SEEL
SEEL was delisted on the 15th of October, 2024.
3 hedge funds and large institutions have $2.2M invested in Seelos Therapeutics, Inc. Common Stock in 2017 Q2 according to their latest regulatory filings, with 1 funds opening new positions, 0 increasing their positions, 1 reducing their positions, and 0 closing their positions.
50% more funds holding
Funds holding: 2 → 3 (+1)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
48% less capital invested
Capital invested by funds: $4.2M → $2.2M (-$2M)
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 1
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Franklin Resources
San Mateo,
California
|
+$140K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
-$140K |
| 2 |
BIP
Brandes Investment Partners
La Jolla,
California
|
-$38K |
| 3 |
VKH
Virtu KCG Holdings
New York
|
-$22K |
| 4 |
AIM
Acrospire Investment Management
Chicago,
Illinois
|
-$6K |
| 5 |
IP
Intellectus Partners
San Francisco,
California
|
-$3K |
SEEL Hedge Fund Activity: Q2 2017 in Review
3 of the 4,022 institutional investors tracked by Wall St. Rank reported a position in Seelos Therapeutics, Inc. Common Stock (SEEL) for Q2 2017, worth a combined $2.2M — down 48% from $4.2M a quarter earlier.
Buyers outnumbered sellers: 1 fund opened new SEEL positions and 0 closed out — a net gain of 1 holder — while 0 added to existing stakes and 1 trimmed.
The largest buyer was Franklin Resources, opening a new position worth an estimated $140K. The largest seller was Vanguard Group, cutting an estimated $140K.
- 3 institutional investors held Seelos Therapeutics, Inc. Common Stock (SEEL) as of Q2 2017, up from 2 in Q1 2017.
- Funds reported $2.2M of Seelos Therapeutics, Inc. Common Stock stock for Q2 2017, down 48% quarter-over-quarter.
- 1 fund opened new Seelos Therapeutics, Inc. Common Stock positions in Q2 2017 and 0 closed out, a net change of +1 holder.
- The largest Seelos Therapeutics, Inc. Common Stock buyer in Q2 2017 was Franklin Resources, an estimated $140K added.
- The largest Seelos Therapeutics, Inc. Common Stock seller in Q2 2017 was Vanguard Group, an estimated $140K sold.
Based on aggregated 13F filings for Q2 2017.